High-Dose Proton/Photon RT + Surgery of Sarcomas of the Thoracic, Lumbar Spine/Sacrum

Mesenchymal Tumor Clinical Trial

Official title:

High-Dose Proton/Photon RT + Surgery of Sarcomas of the Thoracic, Lumbar Spine/Sacrum

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00592345
• Other study ID #: 97-502
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: December 28, 2007
• Last updated: February 2, 2017
• Start date: May 1999
• Est. completion date: March 2016

Study information

• Verified date: February 2017
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the effectiveness of high dose radiation administered by both proton and photon therapy. Radiation is an effective treatment for many types of tumors and it is thought that radiation alone, when given in much higher doses over a shorter period of time, may be more effective in controlling recurrence of sarcoma.

Description:

• In this study three types of radiation will be used: standard radiation (called photon); alternative form of radiation called proton beam therapy; and a localized radiation applicator plaque that can be applied to the surface of the dura (the fibrous outer envelope that surrounds the spinal cord and fluid surrounding the spinal cord) at time of surgical removal of the tumor.

• Radiation treatments (photon and proton) and possibly surgical removal of portions of the tumor with intraoperative radiation delivery to the surface dura with intraoperative radiation delivery will be performed over a period of 12 weeks. As part of the treatment planning process, participants will need two treatment planning CT scans and 2-3 treatment planning sessions.

• Participants will receive, in total, 39-43 photon/proton treatments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: March 2016
• Est. primary completion date: March 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathological diagnosis of malignant mesenchymal tumor of the thoracic/lumbar/spine/sacrum or paraspinal soft tissues involving nerve roots or extending into spinal canal. Inter-osseous bone sarcomas are to be managed by wide resectional surgery for patients that are medically operable.

• Patient tumor status: 1) post biopsy or post resection with gross residual disease 2) post grossly complete resection but with margins positive or very close or tumor spill or cut through

• Lesion may be primary or recurrent after prior surgery

• No clinical, radiographic or other evidence of distant metastasis

• Fit for the exposure of the affected vertebral segment

• Life expectancy of greater than 36 months

• KPS equal to or greater than 70

• 18 years of age or older

• Declines radical surgery

• No prior radiation treatment to the affected spine region

Exclusion Criteria:

• Pregnancy

• Disease/conditions characterized by high radiation sensitivity. These include genetic diseases, such as ataxia telangiectasia. Major local conditions which are the local tolerance viz., multiple surgical procedures, serious local injuries.

• No evident cord/cauda malfunction for causes other than effects of local tumor growth or due to metabolic effects of tumor

Related Conditions & MeSH terms

• Mesenchymal Tumor
• Sarcoma

Intervention

Radiation:
• Proton Beam Radiation
Administered over a period of 12 weeks.
• Photon Beam Radiation
Administered over a period of 12 weeks.
• Interoperative radiation
Radioactive plaque applied at the time of surgical removal of the tumor.

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To define the efficacy of high dose fractionated radiation alone or combined with surgery in this patient population.		3 years
Secondary	To evaluate the acute and later tolerance in 50 patients of high dose proton/photon radiation treatment.		3 years